688796 百奥赛图
已收盘 04-24 15:00:00
资讯
新帖
简况
港股异动 | 百奥赛图-B(02315)早盘涨超4% 25年利润端爆发式增长 BD授权打开长期成长弹性
智通财经 · 04-24 10:27
港股异动 | 百奥赛图-B(02315)早盘涨超4% 25年利润端爆发式增长 BD授权打开长期成长弹性
每周股票复盘：百奥赛图（688796）2025年营收增40.63%
证券之星 · 04-19
每周股票复盘：百奥赛图（688796）2025年营收增40.63%
百奥赛图（688796）披露2025年度持续督导跟踪报告，4月17日股价下跌2.2%
证券之星 · 04-17
百奥赛图（688796）披露2025年度持续督导跟踪报告，4月17日股价下跌2.2%
4月15日百奥赛图涨5.14%，平安港股医疗优选股票(QDII)A基金重仓该股
证券之星 · 04-15
4月15日百奥赛图涨5.14%，平安港股医疗优选股票(QDII)A基金重仓该股
港股异动 | 百奥赛图-B(02315)尾盘涨超7% AI自动化体系有望加速“千鼠万抗”潜力释放
智通财经 · 04-14
港股异动 | 百奥赛图-B(02315)尾盘涨超7% AI自动化体系有望加速“千鼠万抗”潜力释放
每周股票复盘：百奥赛图（688796）与四环医药战略合作
证券之星 · 04-05
每周股票复盘：百奥赛图（688796）与四环医药战略合作
百奥赛图涨8.50%，信达证券二个月前给出“买入”评级
证券之星 · 04-03
百奥赛图涨8.50%，信达证券二个月前给出“买入”评级
港股百奥赛图-B涨超6%
每日经济新闻 · 04-02
港股百奥赛图-B涨超6%
百奥赛图-B午前涨超5% 与百奥赛图正式签署战略合作协定
新浪港股 · 04-02
百奥赛图-B午前涨超5% 与百奥赛图正式签署战略合作协定
港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发
智通财经 · 04-02
港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发
智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长：4月石油供应缺口将达到3月的两倍
智通财经 · 04-02
智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长：4月石油供应缺口将达到3月的两倍
CRO行业回暖了？百奥赛图去年净利润增超400%！模式动物营收增长近6成
时代周报 · 04-01
CRO行业回暖了？百奥赛图去年净利润增超400%！模式动物营收增长近6成
四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发
智通财经 · 04-01
四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发
净利跑出416%增速，百奥赛图-B(02315)迎来商业化兑现期
智通财经 · 03-30
净利跑出416%增速，百奥赛图-B(02315)迎来商业化兑现期
每周股票复盘：百奥赛图（688796）2025年归母净利润1.73亿元，同比上升416.37%
证券之星 · 03-29
每周股票复盘：百奥赛图（688796）2025年归母净利润1.73亿元，同比上升416.37%
百奥赛图（688796）披露合作伙伴双抗ADC药物获FDA临床试验批准，3月27日股价上涨12.68%
证券之星 · 03-27
百奥赛图（688796）披露合作伙伴双抗ADC药物获FDA临床试验批准，3月27日股价上涨12.68%
百奥赛图涨12.68%，信达证券二个月前给出“买入”评级
证券之星 · 03-27
百奥赛图涨12.68%，信达证券二个月前给出“买入”评级
港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长
智通财经 · 03-27
港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长
百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可，合作迈入关键里程碑
智通财经 · 03-26
百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可，合作迈入关键里程碑
百奥赛图（688796）披露2025年年度报告，3月26日股价下跌2.82%
证券之星 · 03-26
百奥赛图（688796）披露2025年年度报告，3月26日股价下跌2.82%
加载更多
公司概况
公司名称：
百奥赛图(北京)医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2025-12-10
主营业务：
百奥赛图(北京)医药科技股份有限公司的主营业务是基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务。公司的主要产品是基因编辑服务、创新模式动物销售、临床前药理药效评价服务、抗体开发、创新药合作研发。公司全面的创新模式动物产品和大规模动物生产与体内外药效研究相结合，可为全球生物技术及大型制药公司客户提供疾病模式动物和体内药理服务。
发行价格：
26.68
{"stockData":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"百奥赛图","latestPrice":102.88,"timestamp":1777014000000,"preClose":99.41,"halted":0,"volume":1800660,"delay":0,"changeRate":0.0349,"floatShares":35887600,"shares":447000000,"eps":0.7001,"marketStatus":"已收盘","change":3.47,"latestTime":"04-24 15:00:00","open":97.63,"high":104.41,"low":97.45,"amount":183000000,"amplitude":0.07,"askPrice":102.89,"askSize":8,"bidPrice":102.88,"bidSize":144,"shortable":0,"etf":0,"ttmEps":0.7001,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":99.41,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":109.35,"lowLimit":89.47,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446898420,"isCdr":false,"pbRate":21.14,"roa":"--","peRate":146.950436,"roe":"16.85%","epsLYR":0.43,"committee":0.121107,"marketValue":45977000000,"turnoverRate":0.0502,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-27。","afterMarket":{"amount":20576,"volume":200,"close":102.88,"buyVolume":0,"sellVolume":0,"time":1777016037559,"indexStatus":"已收盘 04-24 15:30:00","preClose":99.41},"hkstockBrief":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":60,"timestamp":1777018107004,"preClose":57.25,"halted":0,"volume":1850500,"delay":0,"premium":"-49.12"},"floatMarketCap":3692000000},"requestUrl":"/m/hq/s/688796","defaultTab":"news","newsList":[{"id":"2629505895","title":"港股异动 | 百奥赛图-B(02315)早盘涨超4% 25年利润端爆发式增长 BD授权打开长期成长弹性","url":"https://stock-news.laohu8.com/highlight/detail?id=2629505895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629505895?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:27","pubTimestamp":1776997653,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B早盘涨超4%，截至发稿，涨4.1%，报59.6港元，成交额2645.96万港元。消息面上，消息面上，百奥赛图发布2025年度业绩，公司实现营业收入13.79亿元，同比增长40.63%，归母净利润1.73亿元，同比增长416.37%，扣非净利润1.16亿元，同比增长405.39%。继2024年首次扭亏后，公司2025年利润端呈现爆发式增长。未来海外高毛利业务有望持续扩张以及后续高频BD合作有望陆续兑现，有望持续为公司注入强劲的长期业绩动能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK0216","02315","BK4588","688796","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628756465","title":"每周股票复盘：百奥赛图（688796）2025年营收增40.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628756465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628756465?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:51","pubTimestamp":1776534668,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百奥赛图报收于98.66元，较上周的101.13元下跌2.44%。本周关注点来自公司公告汇总：百奥赛图2025年营业收入同比增长40.63%。中国国际金融股份有限公司出具关于百奥赛图（北京）医药科技股份有限公司2025年度持续督导工作现场检查报告。检查期间为2025年12月10日至12月31日，覆盖公司治理、内部控制、信息披露、募集资金使用、关联交易、对外担保及经营状况等方面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274986","title":"百奥赛图（688796）披露2025年度持续督导跟踪报告，4月17日股价下跌2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274986?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:17","pubTimestamp":1776417476,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百奥赛图报收于98.66元，较前一交易日下跌2.2%，最新总市值为440.91亿元。该股当日开盘100.11元，最高101.0元，最低98.0元，成交额达1.7亿元，换手率为4.77%。公告显示，中金公司作为保荐人，对百奥赛图2025年度持续督导情况进行报告。报告期内，公司治理、内部控制及信息披露制度有效执行，未发生违法违规或违背承诺事项。研发投入持续增加，核心竞争力未发生重大不利变化。控股股东、董监高持股无变动，无质押、冻结或减持情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700032745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627745404","title":"4月15日百奥赛图涨5.14%，平安港股医疗优选股票(QDII)A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627745404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627745404?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:10","pubTimestamp":1776240629,"startTime":"0","endTime":"0","summary":"证券之星消息，4月15日百奥赛图涨5.14%，收盘报107.35元，换手率6.96%，成交量2.5万手，成交额2.59亿元。重仓百奥赛图的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为平安基金的平安港股医疗优选股票A。平安港股医疗优选股票A目前规模为3.83亿元，最新净值1.0443，较上一交易日下跌1.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216","159557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627418617","title":"港股异动 | 百奥赛图-B(02315)尾盘涨超7% AI自动化体系有望加速“千鼠万抗”潜力释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2627418617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627418617?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:14","pubTimestamp":1776150897,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B尾盘涨超7%，截至发稿，涨7.06%，报61港元，成交额1.14亿港元。消息面上，4月9日，四环医药与百奥赛图正式签署战略合作协定。双方将依托百奥赛图领先的全人抗体开发平台，结合四环医药在药物开发、生产和商业化方面的深厚经验，围绕减重等多个疾病领域的创新药物研发开展合作与交流。AI自动化体系有望加速“千鼠万抗”潜力释放，打造高效率、规模化的研发生产体系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","688796","BK1161","AGIX","AIPO","VXUS","02315","CHAT","BK0216","ARTY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625167946","title":"每周股票复盘：百奥赛图（688796）与四环医药战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625167946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625167946?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:32","pubTimestamp":1775327533,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，百奥赛图报收于112.3元，较上周的92.88元上涨20.91%。本周关注点公司公告汇总：百奥赛图与四环医药达成战略合作，聚焦减重等疾病领域创新药研发。公司公告汇总百奥赛图（北京）医药科技股份有限公司宣布与四环医药控股集团有限公司达成战略合作。双方将依托百奥赛图领先的全人抗体开发平台，结合四环医药在药物开发、生产和商业化方面的经验，围绕减重等多个疾病领域的创新药研发开展合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0216","BK1600","BK1191","00460","688796","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624655907","title":"百奥赛图涨8.50%，信达证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2624655907","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624655907?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:13","pubTimestamp":1775203984,"startTime":"0","endTime":"0","summary":"今日百奥赛图涨8.50%，收盘报112.3元。2026年1月9日，信达证券研究员唐爱金,贺鑫发布了对百奥赛图的研报《公司深度报告：高速成长的生物技术平台，乘风破浪未来可期》，该研报对百奥赛图给出“买入”评级。我们认为百奥赛图是全球领先的生物技术平台型公司，RenMice平台有望贡献高弹性空间，BioMice平台有望贡献稳定现金流，中长期成长性突出，首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300031172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624868522","title":"港股百奥赛图-B涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624868522","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624868522?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:43","pubTimestamp":1775101431,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月2日，百奥赛图-B(02315.HK)涨超6%，截至发稿涨6.3%，报63.3港元，成交额5601.17万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693164980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693164980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","688796","BK0216","BK4585","BK4588","VXUS","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624052499","title":"百奥赛图-B午前涨超5% 与百奥赛图正式签署战略合作协定","url":"https://stock-news.laohu8.com/highlight/detail?id=2624052499","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624052499?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:39","pubTimestamp":1775101140,"startTime":"0","endTime":"0","summary":" 百奥赛图-B盘中涨超6%，截至发稿，股价上涨5.29%，现报62.70港元，成交额5695.47万港元。 四环医药与百奥赛图正式签署战略合作协定。双方将依托百奥赛图领先的全人抗体开发平台，结合四环医药在药物开发、生产和商业化方面的深厚经验，围绕减重等多个疾病领域的创新药物研发开展合作与交流，推动优势互补与资源协同，建立长期、稳定的合作关系。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaqzu2025048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688796","BK1161","BK0216","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624251435","title":"港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2624251435","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624251435?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:59","pubTimestamp":1775091553,"startTime":"0","endTime":"0","summary":"重大事项：百奥赛图-B(02315)与四环医药(00460)达成战略合作 加速减重等多领域创新药研发远东发展(00035)拟出售墨尔本丽思卡尔顿酒店49.9%权益大唐环境(01272)拟斥资约2457.41万元收购报废风电设备荣昌生物(09995)：国家药监局批准双特异性抗体药物偶联物(双抗ADC)注射用RC288开展临床试验易生活控股(00223)：与雅澳供应链启动AI数字供应链战略合作经营业绩","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0043850808.USD","LU2348774022.SGD","LU0293314216.USD","LU0326950275.SGD","SG9999001226.SGD","LU2097828631.EUR","LU0307460666.USD","LU0359202008.SGD","LU1961090484.USD","LU0516423174.USD","BK1119","LU0823414478.USD","LU0650527681.SGD","IE00B0JY6N72.USD","LU2153592121.USD","LU0164865239.USD","LU1251922891.USD","LU0359201612.USD","LU1868837565.USD","LU2399975544.HKD","LU2097828805.USD","SG9999015952.SGD","80175","BK1574","LU0348805143.USD","BK1539","LU0289961442.SGD","LU0165289439.USD","BK1161","LU0054450605.USD","LU0516422440.USD","LU0856984785.SGD","LU0634319403.HKD","IE00BZ08YR35.GBP","LU1242518931.SGD","GELYY","SG9999006514.SGD","LU1813983027.USD","00460","LU0052750758.USD","LU0561508036.HKD","LU0509642566.USD","BK1594","LU0594300419.USD","LU2249611893.SGD","BK1593","LU0588546209.SGD","LU2097828557.USD","LU2357125470.USD","LU1720050803.USD","02315","LU0348735423.USD","LU2039709279.SGD","LU0828238088.HKD","BK1589","002594","LU2097828714.EUR","LU0164872284.USD","LU2449936058.SGD","LU1861219969.SGD","LU1770034418.SGD","LU0865486749.SGD","BK1521","BK1124","LU0143863198.USD","LU0594300179.USD","LU2476274720.SGD","LU0588545904.SGD","LU0593848301.USD","LU0823039010.USD","LU2360107325.USD","81211","LU0543330566.HKD","LU2506951792.HKD","BK1540","LU0214875030.USD","LU0531970944.HKD","LU0979878070.USD","LU0871576103.HKD","LU0315178854.USD","LU1794554557.SGD","LU0449515922.USD","LU0540923850.HKD","LU1880383366.USD","LU0254981946.USD","IE00BZ08YS42.EUR","BK1600","IE00BD6J9T35.USD","LU0314109678.HKD","LU0259732245.USD","LU1282651121.HKD","LU0819121731.USD","LU0819123356.HKD","BK1610","688796","SG9999015986.USD","LU0469268626.HKD","BK1522","LU1868838027.USD","LU0449509016.USD","LU0084288322.USD","LU0211977185.USD","LU0516422952.EUR","LU1880383440.USD","LU0327786744.USD","LU0244354667.USD","BK1582","LU1719994722.HKD","LU0359201885.HKD","LU0708995583.HKD","LU0823414551.USD","LU1303224171.USD","LU0605514214.HKD","LU0269904917.USD","LU1861214812.USD","BK0216","LU0175139822.USD","LU0143863784.USD","SG9999015945.SGD","SG9999006597.SGD","LU1328277881.USD","LU0417516738.SGD","BK4588","SG9999002828.SGD","SG9999002463.SGD","BK1191","BK1509","LU0511384066.AUD","BK1515","LU1188198961.HKD","LU0039217434.USD","LU1023057109.AUD","LU0572944931.SGD","LU0516423091.SGD","LU0463099449.HKD","BK4585","LU0315179316.USD","LU1224444064.USD","LU0417516902.SGD","LU1808992512.USD","LU2476274308.USD","BYDDY","LU0229945570.USD","LU1282651048.USD","LU0348827113.USD","LU2097828474.EUR","LU2294711713.HKD","IE00BZ08YT58.USD","LU0516422366.SGD","EVS.SI","HYDD.SI","SG9999014674.SGD","LU0823038988.USD","LU1868837722.USD","LU0320764599.SGD","LU0505663152.USD","LU0823426480.USD","LU1242518857.USD","LU2778985437.USD","LU0531971595.HKD","LU0823426308.USD","LU0289739343.SGD","BK1240","LU0348825331.USD","LU0289960550.SGD","SG9999015978.USD","LU0588545730.USD","LU0588545490.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624540176","title":"智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长：4月石油供应缺口将达到3月的两倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2624540176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624540176?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:33","pubTimestamp":1775086385,"startTime":"0","endTime":"0","summary":"美国执行载人绕月任务火箭发射升空当地时间4月1日傍晚，美国航空航天局新一代登月火箭“太空发射系统”从佛罗里达州肯尼迪航天中心发射升空，执行“阿耳忒弥斯2号”载人绕月任务。这是美国自1972年以来首次载人飞向月球。据知情人士透露，这家卫星制造与火箭发射公司已以保密方式递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1993786604.SGD","03750","01857","BK1141","02256","BK4585","BK1610","BK1191","LU1960683339.HKD","03759","300750","LU0067412154.USD","BK4570","688796","BK4588","00460","BK1116","LU1152091168.USD","LU1152091754.HKD","LU1807302812.USD","BK1515","XLE","BK1194","06681","BK1161","LU0880133367.SGD","XOP","BK1600","BK1593","BK1576","02315","LU1008478684.HKD","300759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624592752","title":"CRO行业回暖了？百奥赛图去年净利润增超400%！模式动物营收增长近6成","url":"https://stock-news.laohu8.com/highlight/detail?id=2624592752","media":"时代周报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624592752?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:19","pubTimestamp":1775038754,"startTime":"0","endTime":"0","summary":"3月30日，百奥赛图（688796.SH；02315.HK）宣布与日本药企大正制药达成一项平台授权协议。百奥赛图授予大正制药其专有的RenNano?全人仅重链抗体（HCAb）发现平台的使用权，以支持大正制药的内部新药研发项目。根据协议条款，大正制药将利用RenNano?全人纳米抗体小鼠在体内（invivo）生成并筛选全人仅重链抗体，进一步推进相关的下游发现与研究工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692060859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624960675","title":"四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2624960675","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624960675?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:06","pubTimestamp":1775034361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布公告，集团与百奥赛图(北京)医药科技股份有限公司正式签署战略合作协定。双方将立足优势互补与专业协同的合作原则，凭借集团在药物开发、规模化生产及商业化环节的全产业链成熟经验，结合百奥赛图业内领先的AI驱动全人抗体开发平台核心技术，在减重等多个高潜力疾病领域开展创新药物联合研发工作，建立长期稳定、互利共赢的合作关系，共同推动全球前沿创新药的研发落地与商业化布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","AGIX","CHAT","AIPO","BK0216","688796","BK1191","159992","BK1600","06978","BK1593","BK1515","BK1574","BK1161","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623612963","title":"净利跑出416%增速，百奥赛图-B(02315)迎来商业化兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2623612963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623612963?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:06","pubTimestamp":1774832793,"startTime":"0","endTime":"0","summary":"2026年，创新药板块迎来多重利好共振，行业回暖态势明确。2025年，公司模式动物业务收入6.22亿元，同比增长近60%，毛利率超80%，持续贡献稳定现金流。2025年，百奥赛图抗体开发业务实现收入3.32亿元，毛利率达86%;累计签署超350项合作协议，其中2025年就新增150余项。短期业绩利好催化股价上行，叠加长期价值逐步显现，百奥赛图凭借其创新技术、稀缺的商业模式与全球新药研发体系中的有利卡位，有望率先受益于行业景气度回升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","BK0216","688796","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623380506","title":"每周股票复盘：百奥赛图（688796）2025年归母净利润1.73亿元，同比上升416.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623380506","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623380506?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:58","pubTimestamp":1774720688,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百奥赛图报收于92.88元，较上周的77.4元上涨20.0%。业绩披露要点百奥赛图2025年主营收入13.79亿元，同比上升40.63%；归母净利润1.73亿元，同比上升416.37%；扣非净利润1.16亿元，同比上升405.39%。2025年第四季度单季度主营收入4.38亿元，同比上升12.12%；单季度归母净利润5907.3万元，同比下降56.5%；单季度扣非净利润5830.72万元，同比下降51.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820586","title":"百奥赛图（688796）披露合作伙伴双抗ADC药物获FDA临床试验批准，3月27日股价上涨12.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820586","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622820586?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:08","pubTimestamp":1774620504,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百奥赛图报收于92.88元，较前一交易日上涨12.68%，最新总市值为415.08亿元。该股当日开盘82.19元，最高93.17元，最低81.19元，成交额达2.58亿元，换手率为8.1%。近日，百奥赛图发布港股自愿性公告披露：其合作伙伴NEOK Bio的双抗ADC药物NEOK002获得美国FDA的新药临床试验批准，该药物靶向EGFR/MUC1，用于实体瘤治疗。NEOK Bio计划于2026年第二季度启动I期临床试验，预计2027年公布初步临床数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700049333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873849","title":"百奥赛图涨12.68%，信达证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873849?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:14","pubTimestamp":1774599266,"startTime":"0","endTime":"0","summary":"今日百奥赛图涨12.68%，收盘报92.88元。2026年1月9日，信达证券研究员唐爱金,贺鑫发布了对百奥赛图的研报《公司深度报告：高速成长的生物技术平台，乘风破浪未来可期》，该研报对百奥赛图给出“买入”评级。我们认为百奥赛图是全球领先的生物技术平台型公司，RenMice平台有望贡献高弹性空间，BioMice平台有望贡献稳定现金流，中长期成长性突出，首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","601059"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622045816","title":"港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622045816","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622045816?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:39","pubTimestamp":1774579145,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超12%，截至发稿，涨11.99%，报60.25港元，成交额7808.72万港元。消息面上，百奥赛图发布2025年度业绩，公司实现营业收入13.79亿元，同比增长40.63%，归母净利润1.73亿元，同比增长416.37%，扣非净利润1.16亿元，同比增长405.39%。值得关注的是，百奥赛图全球化布局成果卓越，2025年海外收入占比近70%，服务网络覆盖美国，欧洲和亚太市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","688796","BK1161","BK0216","02315","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622986952","title":"百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可，合作迈入关键里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2622986952","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622986952?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:35","pubTimestamp":1774535741,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B 发布公告，本公司合作伙伴NEOK Bio, Inc.近日获得美国食品药品监督管理局对其在研新药NEOK002的新药临床试验申请批准。NEOK Bio计划于2026年第二季度启动I期临床试验，并预计于2027年公布初步临床数据。此次IND获批标志着NEOK002项目取得重要里程碑进展。NEOK002基于百奥赛图自主开发并于2024年对外授权的双特异性抗体构建，由NEOK Bio进一步推进 ADC药物开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","688796","02315","BK1161","BK4585","IND","BK0216","ADC","BK4231","BK4080","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622002866","title":"百奥赛图（688796）披露2025年年度报告，3月26日股价下跌2.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002866","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622002866?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:25","pubTimestamp":1774535120,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，百奥赛图报收于82.43元，较前一交易日下跌2.82%，最新总市值为368.38亿元。近日，百奥赛图（北京）医药科技股份有限公司披露《2025年年度报告》。公告显示，公司2025年实现营业收入137,880.84万元，同比增长40.63%；归属于上市公司股东的净利润为17,319.98万元，同比增长416.37%；归属于上市公司股东的扣除非经常性损益的净利润为11,607.78万元，同比增长405.39%。利润总额为18,803.05万元，同比增长337.90%。研发投入占营业收入的比例为31.77%，较上年减少1.27个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777166521295,"stockEarnings":[{"period":"1week","weight":0.0428},{"period":"1month","weight":0.2129},{"period":"3month","weight":0.4722},{"period":"6month","weight":2.8561},{"period":"ytd","weight":0.9559}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥赛图(北京)医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2025-12-10","address":"北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院","registeredCapital":"44689万元","survey":" 百奥赛图(北京)医药科技股份有限公司的主营业务是基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务。公司的主要产品是基因编辑服务、创新模式动物销售、临床前药理药效评价服务、抗体开发、创新药合作研发。公司全面的创新模式动物产品和大规模动物生产与体内外药效研究相结合，可为全球生物技术及大型制药公司客户提供疾病模式动物和体内药理服务。","listedPrice":26.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图,688796,百奥赛图股票,百奥赛图股票老虎,百奥赛图股票老虎国际,百奥赛图行情,百奥赛图股票行情,百奥赛图股价,百奥赛图股市,百奥赛图股票价格,百奥赛图股票交易,百奥赛图股票购买,百奥赛图股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}